Valion Bio notifies availability of press release on Entolimod trial at Sheba Medical Center

Valion Bio, Inc.

Valion Bio, Inc.

VBIO

0.00
  • Valion Bio disclosed a Sheba Medical Center-funded clinical trial to test Entolimod in cancer patients receiving high-dose radiation.
  • Study targets radiation-induced neutropenia, positioning Entolimod for a second development path beyond acute radiation syndrome under the FDA Animal Rule.
  • Protocol finalized; IRB decision expected in Q3 2026, first patient in Q4 2026–Q1 2027, initial data in early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Valion Bio Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607201328PR_NEWS_USPR_____CL07836) on July 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.